Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 6/20 | 0.46 |
| ▸ | CA2 | P00918 | 6/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CA6 | P23280 | 1/20 | 0.46 |
| ▸ | CA5A | P35218 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.46 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27599822 | 0.85 | CA9 (0.50) | SMN1; SMN2KDM4ECA9PSIP1CA1 | |
| SCHEMBL5196180 | 0.80 | CA1 (0.55) | SMN1; SMN2KDM4ECA1CA2MAPT | |
| SCHEMBL2928482 | 0.78 | SMN1; SMN2 (0.66) | SMN1; SMN2KDM4ECA9PSIP1CA1 | |
| SCHEMBL2026104 | 0.78 | BCAT1 (0.55) | KDM4ECA9CA1CA2CA12 | |
| SCHEMBL30825673 | 0.77 | MMP2 (0.61) | CA9CA1CA2CA12CA14 | |
| SCHEMBL7383385 | 0.77 | MMP2 (0.61) | CA9CA1CA2CA12CA14 | |
| SCHEMBL27903861 | 0.76 | BCAT1 (0.53) | KDM4ECA9CA1CA2CA12 | |
| Hydrochloric Acid SCHEMBL7382379 | 0.76 | CA1 (0.48) | SMN1; SMN2CA1CA2ALDH1A1GAA | |
| SCHEMBL28146078 | 0.75 | SMN1; SMN2 (0.51) | SMN1; SMN2KDM4ECA9PSIP1CA1 | |
| SCHEMBL1134875 | 0.73 | CA9 (0.59) | SMN1; SMN2KDM4ECA9PSIP1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022135-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF | 1CBIO INC (US) | 2026-01-22 | — | — | US | disclosed |
| US-12325720-B2 | Ectonucleotide pyrophosphatase-phosphodiesterase-1 (ENPP1) inhibitors and uses thereof | 1CBIO, INC. (US) | 2025-06-10 | — | — | US | disclosed |
| US-20240352046-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF | 1CBIO INC (US) | 2024-10-24 | — | — | US | disclosed |
| EP-4236928-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF | 1Cbio, Inc. (US) | 2023-09-06 | — | — | EP | disclosed |
| US-20220135598-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF | INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) | 2022-05-05 | — | — | US | disclosed |
| WO-2022091048-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF | INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) | 2022-05-05 | — | — | WO | disclosed |
| US-10161929-B2 | Theranostics platform and methods of use | Sanford Burnham Prebys Medical Discovery (US) | 2018-12-25 | — | — | US | disclosed |
| EP-2303353-B1 | DRUG-ELUTING MEDICAL DEVICES | RAMOT AT TEL-AVIV UNIV LTD (IL) | 2018-01-10 | — | — | EP | disclosed |
| US-20160082161-A1 | DRUG-ELUTING MEDICAL DEVICES | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2016-03-24 | — | — | US | disclosed |
| US-20160030476-A1 | Compositions, Methods And Devices For Promoting Wound Healing And Reducing Infection | IASIS MOLECULAR SCIENCES (US) | 2016-02-04 | — | — | US | disclosed |
| EP-1827408-A1 | METHOD FOR TREATING SKIN DISORDERS WITH XANTHOPHYLLS | Nu-Tein Co., Inc. (US) | 2007-09-05 | — | — | EP | disclosed |
| EP-1827400-A2 | TOPICAL SKIN PATCH CONTAINING XANTHOPHYLLS | Nu-Tein Co., Inc. (US) | 2007-09-05 | — | — | EP | disclosed |
| EP-1814540-A2 | COMPOSITIONS USEFUL TO TREAT OCULAR NEOVASCULAR DISEASES AND MACULAR DEGENERATION | Nu-Tein Co., Inc. (US) | 2007-08-08 | — | — | EP | disclosed |
| US-20060134226-A1 | Compositions useful to treat ocular neovascular diseases and macular degeneration | NU-TEIN CO., LTD. | 2006-06-22 | — | — | US | disclosed |
| WO-2006062740-A2 | TOPICAL SKIN PATCH CONTAINING XANTHOPHYLLS | NU-TEIN CO., INC. (US) | 2006-06-15 | — | — | WO | disclosed |
| WO-2006060475-A1 | METHOD FOR TREATING SKIN DISORDERS WITH XANTHOPHYLLS | NU-TEIN CO., INC. (US) | 2006-06-08 | — | — | WO | disclosed |
| US-20060122282-A1 | METHOD FOR TREATING SKIN DISORDERS WITH XANTHOPHYLLS | NU-TEIN CO., INC. | 2006-06-08 | — | — | US | disclosed |
| WO-2006055526-A2 | COMPOSITIONS USEFUL TO TREAT OCULAR NEOVASCULAR DISEASES AND MACULAR DEGENERATION | NU-TEIN CO., INC. (US) | 2006-05-26 | — | — | WO | disclosed |
| US-20050089473-A1 | Potassium channel mediated delivery of agents through the blood-brain barrier | CEDARS-SINAI MEDICAL CENTER | 2005-04-28 | — | — | US | disclosed |
| US-20020042394-A1 | Cobalamin compounds useful as antibiotic agents and as imaging agents | HOGENKAMP HENRICUS P C (US) | 2002-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022135-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF | ENPP1, ENPP3, NCEH1 | SMN1; SMN2 1343/4885KDM4E 4523/4885CA9 1628/4885 |
| US-20060134226-A1 | Compositions useful to treat ocular neovascular diseases and macular degeneration | CFD, VEGFA, CFH | SMN1; SMN2 2277/4885KDM4E 2934/4885CA9 1267/4885 |
| US-20240352046-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF | ENPP1, ENPP3, ENPP2 | SMN1; SMN2 1740/4885KDM4E 3129/4885CA9 2755/4885 |
| US-20220135598-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF | ENPP1, ENPP3, ENPP2 | SMN1; SMN2 1740/4885KDM4E 3129/4885CA9 2755/4885 |
| US-20050089473-A1 | Potassium channel mediated delivery of agents through the blood-brain barrier | KCNN2, KCNN1, KCNN3 | SMN1; SMN2 759/4885KDM4E 1674/4885CA9 294/4885 |
| US-12325720-B2 | Ectonucleotide pyrophosphatase-phosphodiesterase-1 (ENPP1) inhibitors and uses thereof | ENPP1, ENPP3, ENPP2 | SMN1; SMN2 1740/4885KDM4E 3129/4885CA9 2755/4885 |
| US-20160030476-A1 | Compositions, Methods And Devices For Promoting Wound Healing And Reducing Infection | MMP8, IL1B, MMP1 | SMN1; SMN2 2477/4885KDM4E 4618/4885CA9 1848/4885 |
| US-20020042394-A1 | Cobalamin compounds useful as antibiotic agents and as imaging agents | MMAB, BLVRB, AHCY | SMN1; SMN2 2904/4885KDM4E 4257/4885CA9 2140/4885 |
| US-20060122282-A1 | METHOD FOR TREATING SKIN DISORDERS WITH XANTHOPHYLLS | COL1A1, COL2A1, KRT18 | SMN1; SMN2 4229/4885KDM4E 2315/4885CA9 3988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.